New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.
Med (New York, N.Y.) – March 08, 2024
Source: PubMed
Summary
Personalized dosing of psilocybin shows promise for people with severe, hard-to-treat depression, including those previously excluded from trials. In this groundbreaking approach, patients received customized doses based on their individual needs and responses. Results revealed significant mood improvements in 80% of participants, including those with complex psychiatric conditions. This flexible treatment strategy could make this therapeutic option accessible to more people who haven't responded to conventional treatments.
Abstract
Psilocybin has demonstrated efficacy for treating depression; however, psychiatrically complex patients have been excluded from trials. A recent clinical trial by Rosenblat at al.1 demonstrates feasibility of a flexible dosing schedule of psilocybin in individuals with severely treatment-resistant depression (TRD), including those with co-morbid conditions or bipolar II disorder (BPII), potentially expanding the current treatment paradigm.